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Several guidelines have been published about management of chronic GvHD (cGvHD), but the clinical practice still remains
demanding. The Gruppo Italiano Trapianto di Midollo Osseo (GITMO) has planned a prospective observational study on cGvHD,
supported by a dedicated software, including the updated recommendations. In view of this study, two surveys have been
conducted, focusing the management of cGvHD and ancillary therapy in cGvHD, to address the current ‘real life’ situation. The two
surveys were sent to all 57 GITMO centers, performing allografting in Italy; the response rate was 57% and 66% of the interviewed
centers, respectively. The ﬁrst survey showed a great disparity especially regarding steroid-refractory cGvHD, although
extracorporeal photo-apheresis resulted as the most indicated treatment in this setting. Another challenging issue was the strategy
for tapering steroid: our survey showed a great variance, and this disagreement could be a real bias in evaluating outcomes in
prospective studies. As for the second survey, the results suggest that the ancillary treatments are not standardized in many
centers. All responding centers reported a strong need to standardize management of cGvHD and to participate in prospective
trials. Before starting observational and/or interventional studies, a detailed knowledge of current practice should be encouraged.
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INTRODUCTION
The prevalence and severity of chronic GvHD (cGvHD) have
increased during the past 2 decades,1,2 likely because of (1)
increasing use of allogeneic hematopoietic stem cell transplantation
(HCT) in older patients, (2) the widespread use of mobilized blood
cells instead of marrow for grafting and (3) improvements in day-
100 mortality.1,3,4 Up to date, cGvHD still remains the leading cause
of long-term nonrelapse morbidity and mortality following HCT.
Management of cGvHD is challenging because of polymorphic
manifestations and lack of biomarkers for the diagnosis and
assessment of disease activity. Although the National Institute of
Health (NIH) consortium have made a considerable effort for
sharing standardized guidelines published in 2005,5 and more
recently further updated,2 a recent meta-analysis showed little
progress in this ﬁeld.6
On behalf of the Gruppo Italiano Trapianto di Midollo Osseo
(GITMO), two questionnaires were proposed to Italian Centers
performing allogeneic HCT, intended to address the ‘real-life’
management of cGvHD. Although heterogeneity of physician
practice in allogeneic HCT has been demonstrated by many
studies,7–9 these surveys were focused on the practice of the
centers (not single physician) and potential difﬁculties in following
guidelines, with the aim to better design feasible prospective
trials.
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MATERIALS AND METHODS
Invitations to participate in the surveys were emailed to the transplant
program directors of all 57 centers that are part of the GITMO and that are
performing allografting. As the aim was investigating the policies of the
centers and not the single-physician approach, it was asked speciﬁcally to
respond according to the common procedures of the center and not the
individual one; the respondent was the director himself or his delegate.
Two further reminders were sent to nonrespondents. Only one response
per center was received, and surveys were collected using an online survey
tool. The questions of both surveys have been preliminary discussed in a
GITMO Meeting and reviewed by four experts in cGvHD, members of the
GITMO GvHD Consortium and validated by the transplant team of the
Hematology Department of Ancona.
The ﬁrst survey was sent in 2015 and included 41 multiple-choice
questions, with a few more in-depth open-ended questions, focused on
management of cGvHD: use of published guidelines, choice of ﬁrst line of
treatment and handling of steroid-refractory cGvHD (see Supplementary
Files 1a and b).
A second survey was sent in 2016 to investigate the use and diffusion of
ancillary therapy and supportive care in patients affected by cGvHD: it
consisted of 30 multiple-choice questions investigating business organiza-
tion, medical needs, nursing, counseling and consultative medicine (see
Supplementary Files 2a and b).
As applicable, participant and transplant center demographics and
responses are summarized using descriptive statistics.
RESULTS
General issues
In the 6-month time frame, the survey on cGvHD management
was accomplished by 32 respondents (28 adult transplant centers
and 4 pediatric centers) for a response rate of 56%, similar to other
reports.7–9 In 2015, the median number of allogeneic transplants
in the responding centers was 22 (range 2–78); 17/32 respondents
belonged to academic hospital and 15 to community hospital.
Answers from pediatric and adult centers did not differ, but only
four pediatric centers completed the survey.
Twenty-nine centers referred to published guidelines for cGvHD
management (Table 1). For diagnosis, most of them (N= 14)
referred to guidelines proposed by the NIH or similar,2,5,10,11
whereas the most cited guidelines for treatment were those of
British and EBMT (European Society for Blood and Marrow
Transplantation),12–14 and those proposed by Wolff et al.15
(Table 1). The NIH, British and European guidelines differ only
for small details, but only 13/33 centers found them fully
satisfactory. The main reasons for lack of satisfaction concerned
the second-line approach (when to start treatment, treatment
choice and/or absence of clear evidence in this setting) (Figure 1).
At the time of survey, only three centers had a cGvHD trial open,
all for steroid-refractory cGvHD.
First-line treatment
The criterion to start systemic treatment was the occurrence of
moderate or severe cGvHD deﬁned as per NIH indications5,16 in 25
centers, and as per Shulman et al.17 in 1 center, whereas 4 centers
also considered the presentation with bad prognostic features,
regardless the grading, and 2 centers treated all patients
diagnosed with cGvHD.
All centers indicated prednisone as ﬁrst-line treatment that was
started at the dose of 1 mg/kg in 27/32 centers, at 0.5 mg/kg in 4
centers and at 2 mg/kg in 1 center. Four centers used prednisone
as single agent, whereas 28 preferred an association with other
treatments: extracorporeal photo-apheresis (ECP, N= 25), calci-
neurine inhibitors (N= 17) and mycophenolate mofetil (MMF,
N= 11), sirolimus (N= 2), imatinib (N= 2), pentostatin (N= 1) and
rituximab (N= 1).
A broad inter-center variety has been reported regarding the
duration of treatment, as well as the indication to and the choice
of steroid-sparing agents. All but 6 centers used the updated NIH
criteria to deﬁne response. Objective measurements (that is,
pulmonary function and lab tests), patient reports and ability to
treatment discontinuation were scored as very relevant for
response judgment, whereas physician opinion was scored as
medium. To evaluate response to treatment, 12 centers con-
sidered a ﬁxed timepoint (such as 3 months), whereas 18 believed
that response should be assessed at multiple timepoints to
determine whether the beneﬁt is sustained (2 not answered). In
case of complete response, 30/32 centers tapered steroid slowly,
but there was no uniformity on the deﬁnition of slow taper
(Figure 2). In case of partial response, 18/33 centers tapered
steroid as slowly as in complete response, 11/33 tapered steroid
more rapidly and added another agent (3 no response).
Refractory cGvHD
Treatment failure, steroid refractoriness, dependency or intoler-
ance were the main reasons for second-line therapy. Treatment
failure was deﬁned as follows: (1) progression or lack of response;
and (2) clinically relevant ﬂares of cGvHD within the ﬁrst 3 months:
2 ﬂares in 3 months according to 15 centers, 1 ﬂare in 7 centers, 3
ﬂares in 7 centers and 2 centers waited for more than 3 ﬂares
(1 did not answer). Twenty-two centers adopted the deﬁnition of
Table 1. Cited guidelines
Diagnosis Na First-line
treatment
N Second-line
treatment
N
Dignan et al.12 9 Dignan et al.12 9 Dignan et al.12 9
Filipovich et al.5 6 Wolff et al.22 9 Flowers et al.10 5
Flowers et al.10 5 Flowers et al.10 5 Wolff et al.15 2
Jagasia et al.2 2 Ruutu et al.14 5 Hildebrant et al.30 1
Carpenter11 2 Hildebrant
et al.30
1
Hildebrant et al.30 1 Dignan et al.13 1
Dignan et al.13 1
aNumber of centers referring to the guideline.
16
14
12
10
8
6
4
2
0
No
response
No Yes Not fully
satisfied
Lack of comprehensive
indications about second line
therapy (N=4)
Clear definition of treatment
failure (N=3)
Lack of evidence based decision
 (N=2)
More details needed about
tapering (N=2)
First line terapy with steroid +/-
CNI not sufficient (N=1)
Too complicated (N=1) and no
response (N=2)
Figure 1. Are you satisﬁed by the current guidelines about
chronic GvHD?
10
9
8
7
6
5
C
en
te
rs
4
3
2
1
0
- 25%/week - 15%/week - 5-10%/week No response
- 10%/week - 5%/week - 12.5%/week in 22 weeks
Figure 2. How did you manage steroid taper?
‘Real-life’ in chronic GvHD
L Giaccone et al
59
© 2018 Macmillan Publishers Limited, part of Springer Nature. Bone Marrow Transplantation (2018) 58 – 63
steroid dependency proposed by NIH: 40.25 mg/kg/day needed
to prevent recurrence or progression of manifestations as
demonstrated by unsuccessful attempts to taper the dose to
lower levels on at least 2 challenges, separated by at least 8
weeks.18 Six centers did not agree to wait 8 weeks and used a 3–5-
week time frame instead, 3 centers disagreed with NIH criteria18
without specifying their policy and 2 centers did not answer.
Uncontrolled diabetes, hypertension, osteoporosis and psychosis
were scored by at least 15 centers as main reasons for steroid
intolerance.
Of the 32 centers, 26 usually considered second-line therapy
between 4 and 8 weeks after initial approach. After the initial
failure, 24 centers would use a different drug, whereas 7 would
not (2 not answered). Sixteen centers had a policy for the choice
of second-line treatment, and the choice was customized
according to organ involvement and patient conditions in 24/32
centers (Table 2). Seven centers declared a policy for third line of
treatment (Table 2). Overall, calcineurine inhibitors, ECP and MMF
were the most used treatments for refractory cGvHD: calcineurine
inhibitors regardless of the involved organ, ECP and sirolimus for
skin, lung and gastrointestinal involvement, imatinib for skin and
lung, inﬂiximab and MMF for liver and gastrointestinal and
rituximab for skin.
ECP was available in 25/32 centers (78%): ECP is delivered via
‘closed’ in 7 and via ‘open’ system in 16 centers. Patients were
treated with ECP on 2 consecutive days at weekly intervals for the
ﬁrst month, then waned according to different schedules in 10 of
the 25 centers; the ECP program was not declared in 11 centers,
whereas it was as follows in the others: 2 consecutive days every
other week (N= 2), 2 consecutive days weekly for 2–3 months
(N= 1) and once weekly (N= 1). As shown in Table 2, ECP is often
used for refractory cGvHD with cutaneous and mucosal
involvement.
At the time of survey, 14 and 5 centers had 10–20 and 420
patients on active treatment for cGvHD, respectively. Figure 3
shows patient distribution according to centers and ongoing
treatments.
Ancillary therapies and supportive care interventions
The survey on ancillary therapy was completed by 38 centers (32
adults and 6 pediatric), for a response rate of 67%, without
differences raised from pediatrician centers. In 2015, the median
number of transplants in the responding centers was 26.
The ﬁrst set of questions focused on business organization
(guidelines, presence of medical and nurses standard operating
procedures (SOPs)). All centers declared to be compliant with the
ﬁrst consensus including the NIH recommendations,19 and 31 out
38 had active projects or dedicated personnel to at least one
aspect of ancillary therapy in their transplant programs. However,
comprehensive medical procedures focused on topical therapies
and drug-free collateral interventions were declared by 7 centers
only. Fourteen centers did not mention ancillary therapies in their
SOPs. Only 10 out 38 centers had speciﬁc SOPs for nursing care,
whereas 13/38 centers included nurse tasks into some
medical SOPs.
Then, the survey inquired about the presence of speciﬁc SOPs
for each organ potentially target of ancillary therapies. As
expected, the most covered issue was prevention and manage-
ment of infectious disease (31/38 centers had dedicated SOPs),
followed by oral (25 centers), lung (21), gynecologic (20) and eye
care (18); neurocognitive functioning, depression and anxiety
together were mentioned by all pediatric centers and only 7 adult
ones. The results indicated that most of the centers have SOPs
including some aspects of ancillary therapies, but very few of
them accomplished all organs possibly involved. Similarly, many
centers referred to specialists for multidisciplinary approach of
cGvHD complications; however, 23/38 complained of the lack of
consultant experts on organ-speciﬁc manifestation of cGVHD.
Consequently, very few consultants felt competent enough to
build a network of GITMO panel of experts.
Further questions investigated the degree of counseling about
cGvHD late complications and quality of life post HCT. The
majority (31/38) of centers addressed these topics before HCT,
although only 20 of them believed to be exhaustive.
Future developments
All responding centers reported a strong need for and willingness
to standardize ﬁrst-line approach to cGvHD as, despite the
accordance in the use of prednisone, the practical aspects
remained uncertain: dose, management of toxicity, duration,
taper and deﬁnition of common response criteria. Furthermore,
there was a strong interest in prospective trials for steroid-
refractory cGvHD. Only 2 centers have already had a protocol
open for refractory GvHD.
Furthermore, all centers agreed to an incoming GITMO
clarifying note on allogeneic HCT complications (GvHD, late
complications and quality of life), properly revised, that may be
used by all Italian transplant centers. With this platform, the
GITMO GvHD Consortium designed a prospective censoring of
cGvHD onset supported by a speciﬁc software based on the NIH
diagnostic and response criteria.
DISCUSSION
Despite the high level of knowledge of the published guidelines,
this survey showed a great disparity in the management of
cGvHD, especially for steroid-refractory disease. Similarly, an
international survey to assess the uptake of NIH recommendations
conducted by EBMT–National Cancer Institute Chronic GVHD Task
Force identiﬁed the therapeutic management of steroid-refractory
cGvHD as the highest priority for research.20 In a group of 235
patients with NIH-deﬁned cGvHD, the median duration of
systemic treatment from time of original onset was 28.7 months
(range, 0.9–115 months),21 meaning that the impact of this rare
Table 2. Centers’ choice for refractory cGvHD according to organ
involvement
Second-line treatments
(10 centers)
Third-line treatments
(3 centers)
Skin
mucosa
GI Liver Lung Skin
mucosa
GI Liver Lung
CNI 2 2 3 2 0 0 0 0
PUVA 1 0 0 0 0 0 0 0
ECP 7 4 3 2 1 1 2 1
Imatinib 3 0 0 7 2 0 0 1
Rituximab 3 0 0 0 2 0 0 0
Sirolimus 1 1 0 2 0 1 0 1
Methotrexate 1 0 1 0 2 0 0 1
High-dose
steroids
0 0 0 1 0 0 0 0
MMF 0 2 4 0 0 0 2 0
Anti-TNFα 0 3 1 0 0 1 0 0
Azathioprine 0 1 1 0 0 0 1 0
Pentostatin 0 2 0 0 0 1 0 0
Montelukast 0 0 0 1 0 0 0 0
Azitromycin 0 0 0 1 0 0 0 0
Abbreviations: cGvHD= chronic GvHD; CNI= calcineurin inhibitor; ECP=
extracorporeal photo-apheresis; GI= gastrointestinal; MMF=mycopheno-
late mofetil; PUVA=photochemotherapy.
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disease is still high, and further efforts should be done to improve
treatment and quality of life.
This survey has been planned not only with the aim of
collecting reliable information about the real-life practice in the
Italian centers, but also because a new prospective observational
study in newly diagnosed cGvHD was planned in the Italian
GITMO centers. This noninterventional study will focus both on
response evaluation (according to the updated NIH criteria) and
long-term outcome with the support of a dedicated software that
utilizes a complex algorithm to calculate both the single organ
and the global response. In order to start this trial in all centers,
based on a homogeneous platform, there was a general
agreement about the need to deﬁne some basic standards about
the major policies for the cGvHD management in the different
Italian centers. These two surveys have been planned in order to
have a common background and to speak the same language in
this ﬁeld; this aspect should be considered a true medical need,
not only for some apparently shared deﬁnition of standard ﬁrst-
line treatment (including duration an tapering schedules), but also
for the standardization of the ancillary treatments.
As expected, despite some inter-center disagreements, systemic
corticosteroids were reported to be the ﬁrst-line treatment for
cGvHD in all GITMO centers; however, most of the centers
associated steroids with ECP upfront, with the aim of increasing
response rate and sparing steroids. The use of prednisone as ﬁrst-
line therapy is indeed widely supported by literature,10,12,14,22 but
randomized trials did not show any beneﬁt from adding other
drugs such as MMF,23 azathioprine,24 thalidomide25 or
hydroxychloroquine26 to initial treatment of cGvHD. Furthermore,
a trial comparing cyclosporine plus prednisone with prednisone
alone showed no statistically signiﬁcant differences in survival or
the duration of treatment.27 As for other alternative treatments
(such as ECP) to be associated upfront with steroids, there are no
clear evidences supporting its association, although this approach
is theoretically attractive, given its tolerability and efﬁcacy as
second-line treatment.
Regarding ﬁrst-line treatment, another challenging issue is the
strategy for tapering steroid: our survey showed a great variance,
mainly because of concern about side effects, although a rapid
taper may cause cGvHD ﬂares. A prototypic taper schedule
proposed by the Seattle group10 is designed to approximate a 20
to 30% dose reduction every 2 weeks, with smaller absolute
decrements toward the end of the taper schedule, with
adjustment according to disease response and toxicities.
General indications for secondary treatment include worsening
manifestations in a previously affected organ, development of
manifestations in a previously unaffected organ, absence of
improvement after 1 month of treatment or inability to decrease
the dose of prednisone below 1.0 mg/kg per day within 2
months.10,15,18 In the GITMO survey, the general concepts
appeared preserved, although there is some variability in the
details mainly because of concerns about drug side effects as well
as disease severity.
No consensus has been reached regarding the optimal choice
of agents for secondary treatment of cGvHD. Treatment choices
were based on physician experience, ease of use, need for
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monitoring, kind of potential toxicity and risk of exacerbation of
preexisting comorbidity.10,15 Reports from the retrospective and
prospective studies on this ﬁeld indicated high response rates, but
results remain difﬁcult to interpret because of deﬁciencies in study
design.6,10 As consequence, in a recent consensus conference,
steroids only achieved a strength of evidence level BIII-I, whereas
all other options were graded less.15 According to the cGvHD
survey, ECP and MMF were the most widely used treatments,
other than rechallenge with steroids and calcineurine inhibitors,
and this is in line with most of the published indications.15
ECP was available in 25/33 centers and widely used, although
with different schedules and not on many patients (Figure 3b).
Recent recommendations from the Italian Society of Hemapher-
esis and Cell Manipulation and the GITMO included ECP in both
adults and pediatric patients with cGvHD, either steroid resistant
or steroid dependent.28 ECP increases the costs for the manage-
ment of GvHD, but the clinical improvement obtained through
ECP makes the incremental costs economically ‘acceptable’.28
Steroid-refractory cGvHD is an orphan disease without
approved therapy, has low appeal for the companies, and this
disease is very difﬁcult to manage, with multiorgan involvement
and unpredictable trajectory and response. The inter-center
discrepancies in its management reﬂected more the complexity
and polymorphism of the disease than the lack of clear and
trusted guidelines. In 2011, Wolff et al.15 published a consensus on
the current evidence of treatment options for steroid-refractory
cGvHD: ECP, thalidomide and methotrexate showed higher
efﬁcacy on mucocutaneus manifestations, rituximab on sclero-
derma and autoantibody-mediated cytopenia, etanercept and
inﬂiximab in gastrointestinal GvHD and imatinib, on the basis of its
antiﬁbrotic activity, on sclerodermic and mild lung manifestations.
Although different treatment options are available, the sparse
evidence for most treatment entities indicates the urgent need for
speciﬁc trials.
The delayed immune reconstitution, caused by disease and
treatment targeting the immune system, the refractory nature of
cGvHD-related ﬁbrosis and the limited success of systemic
immunomodulatory treatments lead to signiﬁcant persistence of
morbidity for prolonged periods of time. Thus, ancillary therapies
and supportive care became central components in the long-term
management of cGvHD after HCT for most of the centers. For a
comprehensive patient care, multidisciplinary approach involving
different specialists is mandatory; however, lack of dedicated
consultants and personnel emerged as the main pitfall in the
survey, and more efforts are required in this ﬁeld.
A particular scenario of jammed drug development happened;
indeed, the overestimation of the response rate generated a
plethora of promising drugs/interventions, making it difﬁcult to
select a shared investigational drug to compare with an undeﬁned
standard treatment. Today, after a long period of stagnation, new
approaches for cGvHD treatment have been proposed thanks to
the recent advances of our understanding of cGvHD
pathophysiology29 these new opportunities should start a new
era of randomized clinical trials in this ﬁeld after decades of small-
size phase 2 trials or retrospective studies. However, a reliable tool
for response evaluation is mandatory in order to avoid an
overestimation of the response rate that is a common ﬁnding in
most old-generation studies where the NIH response criteria have
not been extensively used.
Overall, all involved GITMO centers professed a great interest
and need for prospective trials investigating this setting. In this
view and given the discrepancies enlightened by the surveys, a
prospective observational study conducted by the GITMO is
ongoing. This study will employ a software for cGvHD manage-
ment that allows the automatic calculation of the global severity
score of cGvHD, according to the recent NIH consensus and the
standardized evaluation of the response in the different organs.
Furthermore, these surveys raised the need of common GITMO
SOPs that should include sharing consultants and speciﬁc centers'
skills. These facilities should constitute a solid foundation for
subsequent reliable interventional prospective studies.
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